Lessons Learned and Future Perspectives from the PRO-HF Trial
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Spertus J, Jones P, Sandhu A, Arnold S
. Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 76(20):2379-2390.
DOI: 10.1016/j.jacc.2020.09.542.
View
2.
Green C, Porter C, Bresnahan D, Spertus J
. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000; 35(5):1245-55.
DOI: 10.1016/s0735-1097(00)00531-3.
View
3.
Pokharel Y, Khariton Y, Tang Y, Nassif M, Chan P, Arnold S
. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Cardiol. 2017; 2(12):1315-1321.
PMC: 5814994.
DOI: 10.1001/jamacardio.2017.3983.
View
4.
Solomon S, McMurray J, Anand I, Ge J, Lam C, Maggioni A
. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019; 381(17):1609-1620.
DOI: 10.1056/NEJMoa1908655.
View
5.
Kalwani N, Calma J, M Varghese G, Gupta A, Zheng J, Brown-Johnson C
. The patient-reported outcome measurement in heart failure clinic trial: Rationale and methods of the PRO-HF trial. Am Heart J. 2022; 255:137-146.
PMC: 10069382.
DOI: 10.1016/j.ahj.2022.10.081.
View